Equities

Connect Biopharma Holdings Ltd

CNTB:NMQ

Connect Biopharma Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.24
  • Today's Change0.064 / 5.48%
  • Shares traded5.43k
  • 1 Year change+72.79%
  • Beta-0.2963
Data delayed at least 15 minutes, as of Sep 19 2024 20:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The 2 analysts offering 12 month price targets for Connect Biopharma Holdings Ltd (ADR) have a median target of 7.04, with a high estimate of 8.04 and a low estimate of 6.03. The median estimate represents a 467.73% increase from the last price of 1.24.
High548.9%8.04
Med467.7%7.04
Low386.7%6.03

Earnings history & estimates in CNY

On Sep 12, 2023, losses of -3.90 per share.
Connect Biopharma Holdings Ltd (ADR) reported annual 2023 losses of -7.65 per share on Apr 16, 2024.
Average growth rate+44.63%
More ▼

Revenue history & estimates in CNY

Connect Biopharma Holdings Ltd (ADR) did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.